In this study, we demonstrated that RSK is overexpressed and hyperactivated in AML, and that high levels confer an adverse prognosis, suggesting RSK inhibition as a potential therapeutic target in AML. The gene discussed is RPS6KA2; the disease is acute myeloid leukemia.